menu search

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
– Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – – ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 – ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies […] The post Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting ap... Read More
Posted: Oct 16 2023, 11:05
Author Name: forextv
Views: 112444

Search within

Pages Search Results: